We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Role of Probiotic on Short-chain Fatty Acids (SCFA) and Interleukin-6 (IL-6) Levels in Mice Model of Chronic Obstructive Pulmonary Disease (COPD).
- Authors
Pradana, Andika; Sari, Dina Keumala; Rusda, Muhammad; Tarigan, Amira Permatasari; Wiyono, Wiwien Heru; Soeroso, Noni Novisari; Eyanoer, Putri Chairani; Amin, Mustafa Mahmud
- Abstract
Introduction: Inflammation in COPD patients occurs so extensively that it spills over into systemic circulation, which is characterized by high levels of pro-inflammatory cytokines such as IL-6 in the blood, leading to further damage to various organs in the body. Meanwhile, the gut is filled with millions of microbiotas that release metabolites such as SCFA that translocate to the systemic circulation and may potentially reduce inflammation. Probiotics are expected to repair microbiota dysbiosis, thus having a potency to reduce IL-6 via SCFA pathway. The study aims to assess the effect of probiotic administration on SCFA and IL-6 levels in COPD mice model. Methods: Mice C57BL/6 strain were grouped into KN (healthy mice), KP (COPD mice), P1 (COPD mice treated with bronchodilators), P2 (COPD mice treated with probiotics) and P3 (COPD mice treated with bronchodilators and probiotics). Induction of the COPD model was carried out by cigarette-smoking method 2 times a day for 12 weeks. The probiotic used is 26 milligrams of L-Bio (containing 109 CFU of bacterial strains/gram). SCFA was measured by gas-chromatography form caecum digesta, and IL-6 was measured by ELISA. Results: SCFA levels at the end of experiment were KN(14.0±4.10), KP(4.8±1.78), P1(21.5±7.73), P2(35.9±16.3) and P3(31.7±17.49) mmol/L. There were significant differences in SCFA levels among those groups (p<0.001). IL-6 levels were KN(13.0±2.24), KP(19.4±6.71), P1(17.9±4.94), P2(13.5±0.43) and P3(14.3±2.15) pg/mL. There were significant differences in IL-6 levels among those groups (p=0.03). There was also a significant association between SCFA and IL-6 levels (p=0.02), proving that metabolite produced by gut-microbiota could reduce inflammation not only in the lungs, but also in the systemic level. Conclusion: Probiotic administration could significantly increase SCFA and reduce IL-6 levels in COPD mice models and thus proving that the Gut-Lung Axis really exists.
- Subjects
SHORT-chain fatty acids; CHRONIC obstructive pulmonary disease; ANIMAL disease models; INTERLEUKIN-6; HOOKAHS; PROBIOTICS; WARNING labels
- Publication
Malaysian Journal of Medicine & Health Sciences, 2024, Vol 20, p56
- ISSN
1675-8544
- Publication type
Abstract